Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program
ATLANTA, Jan. 05, 2023 (GLOBE NEWSWIRE) — Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia (“FM”), announced today that its end-of-Phase 2 meeting request with the U.S. Food and Drug Administration (“FDA”) to discuss advancing IMC-1 into Phase 3 development as a treatment for FM has been scheduled for mid-March 2023. At this meeting, the Company will discuss with the FDA plans for a Phase 3 program that would support submission of a new drug application for IMC-1 for the treatment of FM. The Company plans to provide a program update by the end of April following the receipt of formal written feedback from the FDA.
Related news for (VIRI)
- virios therapeutics, inc. and wex pharmaceuticals, inc. announce business combination to form dogwood therapeutics, inc. (nasdaq: “dwtx”)
- Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
- Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
- Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023